AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01911949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single shot femoral nerve block
Description: Nerve block in lingual crease using ultrasound guidance
Study NCT01911949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single shot femoral nerve block
Description: Nerve block in lingual crease using ultrasound guidance
Study NCT02009943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: One time dosing
Study NCT02009943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Goal-directed dosing
Study NCT02595658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal composition
Study NCT02595658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid-Acting Insulin Dose
Study NCT01641042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: 2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
Study NCT01464567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T Tube Spontaneous Breathing Trial
Description: T Tube ventilation for 30 minutes
Study NCT01464567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation
Description: Pressure-Support Ventilation for 30 minutes
Study NCT02125240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125 mg three times daily (375 mg per day) by mouth
Study NCT02125240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 tablet three times daily by mouth
Study NCT02500251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: Belimumab will be administered per study protocol.
Study NCT02500251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered per study protocol.
Study NCT02500251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered per study protocol.
Study NCT02500251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasmapheresis will be administered per study protocol.
Study NCT04547400 — intervention group
Intervention type: OTHER
Intervention: assessment
Description: Assessments of balance, gait, lower extremity position sense, and foot sole sense
Study NCT02230215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation
Description: The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
Study NCT03233074 — intervention group
Intervention type: OTHER
Intervention: Bone marrow analyses
Description: This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
Study NCT03383822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: Humalog lispro 40 IU intranasally
Study NCT02266524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride, very low dose
Study NCT02266524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride, low dose
Study NCT02266524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride, medium dose
Study NCT02266524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride, high dose
Study NCT02709317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Intervention
Study NCT03383822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Diluent intranasally
Study NCT00606060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kogenate (BAY14-2222)
Description: 100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
Study NCT00490230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279396
Study NCT00490230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WR 279396
Study NCT02709317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Study NCT02709317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention
Study NCT02240667 — intervention group
Intervention type: DRUG
Intervention: Dabigatran etexilate
Description: 150 mg or 110 mg capsules twice daily
Study NCT02240667 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonists
Description: International Normalized Ratio (INR) 2-3
Study NCT00637013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acromioplasty
Description: Arthroscopic or open acromioplasty
Study NCT01791387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.~If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions.
Study NCT00359125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifepristone (RU-486)
Description: RU-486, 600 mg/day for 1 week.
Study NCT00359125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 600 mg/day for 1 week.
Study NCT00637013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy according to a standardized protocol
Study NCT03228745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative MBSR
Description: A MBSR program typically consists of 8 weekly 2.5 hour sessions, home practice (typically 45 minutes per day, 6 days per week), and one day retreat. During the program, participants engage in a number of mindfulness practices (e.g., body scan, mindful movement, meditation) and discussions of their experiences, with the aim enhancing awareness to moment-to-moment experiences in a non-judging and accepting manner.
Study NCT00310544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist (Gadopentetate dimeglumine, BAY86-4882)
Description: One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
Study NCT00310544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist (Gadopentetate dimeglumine, BAY86-4882)
Description: One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
Study NCT05720819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined biofeedback-virtual reality device
Description: The study's biofeedback-VR device was developed in collaboration with students and faculty at the University of Washington Global Innovation Exchange program. The system included an Oculus Go mobile VR headset (wireless, portable, head-mounted display, with screen providing a 101° field of view with 2560 x 1440 resolution at a 60-72 Hz frame rate; Oculus VR, LLC, Menlo Park, CA/USA) and with built-in speaker, in addition to a Polar H10 heart rate monitor (electrocardiogram, or ECG, to measure heart rate; Polar Electro Inc., Bethpage, NY/USA), with customized software programmed for the study using the Unity3D game engine (Unity Technologies, Bellevue, WA/USA). Individuals in the experimental arm are asked to use this device for 10 minutes daily, on at least 3 days per week.
Study NCT01760902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Physical Activity
Description: The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
Study NCT00302900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Donation Water Consumption
Description: Consumption of 500 ml of bottled water 30 minutes prior to donating
Study NCT00302900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Tensing Exercise During Donation
Description: Alternating leg lifts at 10-second intervals during donation
Study NCT00302900 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Muscle Tensing Exercise Prior to Donation
Description: Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
Study NCT04713072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 solution for injection
Study NCT04713072 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to ABY-035 solution for injection
Study NCT02607813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: pan-RAF inhibitor
Study NCT02607813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Biological: PDR001 anti-PD1 antibody
Study NCT02596048 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Iomeron
Description: Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
Study NCT03704064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma-Reduction Intervention
Description: Session topics will be based on those tested in a previous pilot study, including: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to physical activity. For example, they will be given strategies to cope with anticipated stigma while exercising in public spaces (e.g., while walking), as well as to challenge self-critical beliefs (e.g., that they are lazy) which may otherwise lead them to avoid exercising. These concrete strategies, along with reducing WBI and improving self-confidence, are intended to increase participants' self-efficacy for and engagement in physical activity.
Study NCT03704064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss (BWL)
Description: This intervention will be based on the Diabetes Prevention Program. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 20 weeks will include self-monitoring, stimulus control, social support, portion sizes, and goal-setting. Those during weeks 21-72 will focus on skills required for weight loss maintenance and relapse prevention. Physical activity will be begin with a prescription of 60 min/wk, and will gradually progress by 10 minutes over 2-4 week intervals until achieving 150 min/wk by week 20, 200 min/wk by week 46, and 250 min/wk by week 72. Participants will be instructed to spread the activity equally across at least 5 days in bouts that are >10 minutes in duration. Moderate intensity will be prescribed with an emphasis on walking; the vast majority of our research participants self-select this form of activity.
Study NCT03704064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Description: This intervention will be based on the Diabetes Prevention Program. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 20 weeks will include self-monitoring, stimulus control, social support, portion sizes, and goal-setting. Those during weeks 21-72 will focus on skills required for weight loss maintenance and relapse prevention. Physical activity will be begin with a prescription of 60 min/wk, and will gradually progress by 10 minutes over 2-4 week intervals until achieving 150 min/wk by week 20, 200 min/wk by week 46, and 250 min/wk by week 72. Participants will be instructed to spread the activity equally across at least 5 days in bouts that are >10 minutes in duration. Moderate intensity will be prescribed with an emphasis on walking; the vast majority of our research participants self-select this form of activity.
Study NCT01286129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal allergen challenge
Description: Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
Study NCT04390165 — intervention group
Intervention type: OTHER
Intervention: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
Description: This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
Study NCT00713076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182
Description: Lens Cleaning Solution Formulation Identification Number 109182
Study NCT04128917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral
Study NCT04128917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAPAE01
Description: RAPAE01/Clarithromycin/Amoxicillin BID peroral
Study NCT00869960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
Study NCT00869960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine
Description: emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
Study NCT00869960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
Study NCT00869960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
Study NCT00823654 — intervention group
Intervention type: OTHER
Intervention: Blood draw and questionnaires
Description: At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment~↓~Tests in the middle of chemotherapy (if applicable):~Blood draw and collection of monthly menstrual calendars ↓~Tests when chemotherapy is over (if applicable):~Blood draw and collection of monthly menstrual calendars~↓~Tests every 4 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire ↓~Tests every 6 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire~↓~Yearly follow-up for about 2 years:~Blood draw collection of monthly menstrual calendars, and questionnaire
Study NCT00823654 — intervention group
Intervention type: OTHER
Intervention: Blood draw and questionnaires
Description: Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent~↓ Register patients at Memorial Sloan-Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)~↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires~↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires
Study NCT04025216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-TnMUC1
Description: Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR)
Study NCT04025216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
Study NCT04025216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
Study NCT03961399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Medical® CRT device with SyncAVTM stimulation function
Description: patients with Abbott Medical® CRT device will be randomized and SyncAVTM stimulation will be activated.
Study NCT03961399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Medical® CRT device with biventricular stimulation (BiV)
Description: patients with Abbott Medical® CRT device will be randomized and biventricular (BiV) stimulation will be activated.
Study NCT04111835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Offering an alternative cervical cancer screening method - hrHPV molecular testing.
Description: Women randomized to this screening strategy group will take a hrHPV molecular test.~hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -> colposcopy~Normal reflex LBC -> repeat LBC in 6 months~Positive - colposcopy~Negative - rescreen in 3 years~HPV-negative - rescreen in 5 years
Study NCT04265677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine FCR
Description: Parents/guardians will be able to join family centered rounds using telemedicine (audio and visual)
Study NCT04265677 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Parents/guardians will not be able to join family centered rounds using telemedicine (audio and visual)
Study NCT02183363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 - Tablet TFII
Study NCT02183363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356 - Tablet TFII
Study NCT02183363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 - Tablet iFF
Study NCT02183363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356 - Tablet iFF
Study NCT02183363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 - Tablet TFIIb
Study NCT02183363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356 - Tablet TFIIb
Study NCT00808340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: multifocal contact lens
Study NCT03924765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered hip exoskeleton
Description: The study team will be testing a powered hip exoskeleton and its capability to improve locomotion in stroke survivors.
Study NCT03446833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The LFP Beta aDBS System
Description: The LFP Beta aDBS System is intended for use in patients receiving DBS for Parkinson's Disease where LFPs may be recorded and analyzed.
Study NCT01758900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 insufflation regulator
Description: The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
Study NCT01758900 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
Study NCT02902939 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: minimal extracorporeal circulation (MEC)
Description: We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.